Drug Database
Back to search

Belgium· BE-AMP-SAM171577-00

Ultravist 370 370 mg/ml

A iopromide product containing iopromide, registered in Belgium by Bayer. The same ATC class is registered in 13 of our 19 countries.

ATC V08AB05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedUltravist 370 370 mg/mlATCV08AB05REGISTER NO.BE-AMP-SAM171577-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about iopromideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Iopromide is registered in 13 of 19 countries.

Countries holding a registration under ATC V08AB05 (iopromide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search iopromide products by name

Iopromide · ATC V08AB05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Iopromide
Manufacturer
Bayer
Country
Belgium (BE)
ATC code
V08AB05
ATC class
Iopromide
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    1280502
    EUR 62.47
  • be_apb
    0773630

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

232 interactions on record for iopromide.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check iopromide against other medicinesHow interaction checks work

Iopromide · interactions on record

232 records

  • 94 severe
  • 55 moderate
  • 83 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Iopromide in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All iopromide products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Ultravist
  • Bulgaria · Ултравист
  • Cyprus · Ultravist 300, Ultravist 370
  • Czechia · Ultravist
  • Germany · Ultravist 300, Ultravist-240
  • Denmark · Ultravist
  • Estonia · Ultravist
  • Spain · Ultravist
  • France · Ultravist
  • Greece · Ultravist
  • Croatia · Ultravist
  • Hungary · Ultravist
  • Italy · Ultravist
  • Lithuania · Ultravist
  • Luxembourg · Ultravist
  • Latvia · Ultravist
  • Malta · Ultravist 370
  • Netherlands · Ultravist
  • Norway · Ultravist
  • Poland · Ultravist 300, Ultravist 370
  • Portugal · Ultravist 240, Ultravist 300
  • Romania · Ultravist
  • Sweden · Ultravist
  • Slovenia · Ultravist
  • Slovakia · Ultravist

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e43dfbd7-5da4-4c70-92df-289c5872016a
GET /v1/drugs/e43dfbd7-5da4-4c70-92df-289c5872016a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection/infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ultravist 370 370 mg/ml",
  "name_fr": "Ultravist 370 370 mg/ml",
  "name_nl": "Ultravist 370 370 mg/ml",
  "amp_code": "SAM171577-00",
  "strengths": [
    "769.0000",
    "769.0000",
    "370.0000",
    "370.0000",
    "0.0050"
  ],
  "pack_count": 1,
  "substances": [
    "Iopromide",
    "Iodine",
    "Sodium Hydroxide",
    "Calcium Disodium Edetate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Iopromide",
  "authorisation_numbers": [
    "BE171577"
  ]
}
API referenceMCP serverPlans

See everything about iopromide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console